NEW YORK (GenomeWeb) – Rheumatology and autoimmune diagnostics firm Exagen Diagnostics has raised $3.95 million, it said in a regulatory document on Monday.

A spokesperson for the Vista, Calif.-based firm declined to comment, and Exagen did not name the investors in the financing round or say how proceeds would be used. According to a document filed with the US Securities and Exchange Commission, the type of securities offered included debt, and securities to be acquired upon the exercise of an option, warrant, or other right to acquire security.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.